Rethinking the diagnostic criteria of polycythemia vera

T. Barbui, J. Thiele, A. M. Vannucchi, Ayalew Tefferi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The aim of this review is to critically address the validity and clinical applicability of three major diagnostic classification systems for polycythemia vera (PV), that is, those proposed by the Polycythemia Vera Study Group (PVSG), the British Committee for Standards in Haematology (BCSH) and the World Health Organization (WHO). Special focus is on which one of the three red cell parameters (hemoglobin - HB, hematocrit - HCT and red cell mass - RCM) should be used as the diagnostic hallmark of PV. The revised BCSH employed a persistently raised HCT level as the first diagnostic criterion in combination with the presence of a JAK2V617F mutation. On the other hand, the WHO classification used a raised HB value as a surrogate for increased RCM in association with molecular markers and for the first time, the bone marrow (BM) morphology was included as a minor criterion. Ongoing controversy and discussion regards the use of certain threshold values for HCT and HB as surrogates for RCM as well as the existence of prodromal-latent disease, so-called masked PV (mPV). It has been shown that mPV can be recognized in patients not meeting the required HB or HCT threshold levels by both the WHO and BCSH criteria. These cases present with the same baseline clinical features as overt PV but present worsened survival. A critical reappraisal of the WHO criteria may suggest either to reduce the thresholds for HB or to consider HCT values as major diagnostic criterion, as in the BCSH, in association with JAK2V617F mutation. The clinical utility of using HCT as reference variable is supported also by results of clinical trials which explicitly recommend to use the HCT threshold for monitoring treatment. In questionable cases as in mPV, BM biopsy examinations should be mandated together with mutation analysis.

Original languageEnglish (US)
Pages (from-to)1191-1195
Number of pages5
JournalLeukemia
Volume28
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Polycythemia Vera
Hematology
Mutation
Erythrocyte Volume
Bone Marrow Examination
Hematocrit
Hemoglobins
Bone Marrow
Clinical Trials
Biopsy
Survival

Keywords

  • bone marrow histology
  • diagnostic criteria
  • masked polycythemia
  • polycythemia vera
  • risk factors for survival

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Rethinking the diagnostic criteria of polycythemia vera. / Barbui, T.; Thiele, J.; Vannucchi, A. M.; Tefferi, Ayalew.

In: Leukemia, Vol. 28, No. 6, 2014, p. 1191-1195.

Research output: Contribution to journalArticle

Barbui, T, Thiele, J, Vannucchi, AM & Tefferi, A 2014, 'Rethinking the diagnostic criteria of polycythemia vera', Leukemia, vol. 28, no. 6, pp. 1191-1195. https://doi.org/10.1038/leu.2013.380
Barbui, T. ; Thiele, J. ; Vannucchi, A. M. ; Tefferi, Ayalew. / Rethinking the diagnostic criteria of polycythemia vera. In: Leukemia. 2014 ; Vol. 28, No. 6. pp. 1191-1195.
@article{ad86a74a4c844aa1a35e361fce643f06,
title = "Rethinking the diagnostic criteria of polycythemia vera",
abstract = "The aim of this review is to critically address the validity and clinical applicability of three major diagnostic classification systems for polycythemia vera (PV), that is, those proposed by the Polycythemia Vera Study Group (PVSG), the British Committee for Standards in Haematology (BCSH) and the World Health Organization (WHO). Special focus is on which one of the three red cell parameters (hemoglobin - HB, hematocrit - HCT and red cell mass - RCM) should be used as the diagnostic hallmark of PV. The revised BCSH employed a persistently raised HCT level as the first diagnostic criterion in combination with the presence of a JAK2V617F mutation. On the other hand, the WHO classification used a raised HB value as a surrogate for increased RCM in association with molecular markers and for the first time, the bone marrow (BM) morphology was included as a minor criterion. Ongoing controversy and discussion regards the use of certain threshold values for HCT and HB as surrogates for RCM as well as the existence of prodromal-latent disease, so-called masked PV (mPV). It has been shown that mPV can be recognized in patients not meeting the required HB or HCT threshold levels by both the WHO and BCSH criteria. These cases present with the same baseline clinical features as overt PV but present worsened survival. A critical reappraisal of the WHO criteria may suggest either to reduce the thresholds for HB or to consider HCT values as major diagnostic criterion, as in the BCSH, in association with JAK2V617F mutation. The clinical utility of using HCT as reference variable is supported also by results of clinical trials which explicitly recommend to use the HCT threshold for monitoring treatment. In questionable cases as in mPV, BM biopsy examinations should be mandated together with mutation analysis.",
keywords = "bone marrow histology, diagnostic criteria, masked polycythemia, polycythemia vera, risk factors for survival",
author = "T. Barbui and J. Thiele and Vannucchi, {A. M.} and Ayalew Tefferi",
year = "2014",
doi = "10.1038/leu.2013.380",
language = "English (US)",
volume = "28",
pages = "1191--1195",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Rethinking the diagnostic criteria of polycythemia vera

AU - Barbui, T.

AU - Thiele, J.

AU - Vannucchi, A. M.

AU - Tefferi, Ayalew

PY - 2014

Y1 - 2014

N2 - The aim of this review is to critically address the validity and clinical applicability of three major diagnostic classification systems for polycythemia vera (PV), that is, those proposed by the Polycythemia Vera Study Group (PVSG), the British Committee for Standards in Haematology (BCSH) and the World Health Organization (WHO). Special focus is on which one of the three red cell parameters (hemoglobin - HB, hematocrit - HCT and red cell mass - RCM) should be used as the diagnostic hallmark of PV. The revised BCSH employed a persistently raised HCT level as the first diagnostic criterion in combination with the presence of a JAK2V617F mutation. On the other hand, the WHO classification used a raised HB value as a surrogate for increased RCM in association with molecular markers and for the first time, the bone marrow (BM) morphology was included as a minor criterion. Ongoing controversy and discussion regards the use of certain threshold values for HCT and HB as surrogates for RCM as well as the existence of prodromal-latent disease, so-called masked PV (mPV). It has been shown that mPV can be recognized in patients not meeting the required HB or HCT threshold levels by both the WHO and BCSH criteria. These cases present with the same baseline clinical features as overt PV but present worsened survival. A critical reappraisal of the WHO criteria may suggest either to reduce the thresholds for HB or to consider HCT values as major diagnostic criterion, as in the BCSH, in association with JAK2V617F mutation. The clinical utility of using HCT as reference variable is supported also by results of clinical trials which explicitly recommend to use the HCT threshold for monitoring treatment. In questionable cases as in mPV, BM biopsy examinations should be mandated together with mutation analysis.

AB - The aim of this review is to critically address the validity and clinical applicability of three major diagnostic classification systems for polycythemia vera (PV), that is, those proposed by the Polycythemia Vera Study Group (PVSG), the British Committee for Standards in Haematology (BCSH) and the World Health Organization (WHO). Special focus is on which one of the three red cell parameters (hemoglobin - HB, hematocrit - HCT and red cell mass - RCM) should be used as the diagnostic hallmark of PV. The revised BCSH employed a persistently raised HCT level as the first diagnostic criterion in combination with the presence of a JAK2V617F mutation. On the other hand, the WHO classification used a raised HB value as a surrogate for increased RCM in association with molecular markers and for the first time, the bone marrow (BM) morphology was included as a minor criterion. Ongoing controversy and discussion regards the use of certain threshold values for HCT and HB as surrogates for RCM as well as the existence of prodromal-latent disease, so-called masked PV (mPV). It has been shown that mPV can be recognized in patients not meeting the required HB or HCT threshold levels by both the WHO and BCSH criteria. These cases present with the same baseline clinical features as overt PV but present worsened survival. A critical reappraisal of the WHO criteria may suggest either to reduce the thresholds for HB or to consider HCT values as major diagnostic criterion, as in the BCSH, in association with JAK2V617F mutation. The clinical utility of using HCT as reference variable is supported also by results of clinical trials which explicitly recommend to use the HCT threshold for monitoring treatment. In questionable cases as in mPV, BM biopsy examinations should be mandated together with mutation analysis.

KW - bone marrow histology

KW - diagnostic criteria

KW - masked polycythemia

KW - polycythemia vera

KW - risk factors for survival

UR - http://www.scopus.com/inward/record.url?scp=84902077783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902077783&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.380

DO - 10.1038/leu.2013.380

M3 - Article

C2 - 24352199

AN - SCOPUS:84902077783

VL - 28

SP - 1191

EP - 1195

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -